Grant: Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
University of Calgary
$105,000.00
Influence of microRNA on Resistance to Proteasome Inhibitors in Multiple Myeloma
EF 2011-12
Résumé
Multiple Myeloma (MM), an incurable disease, is the second most common haematological malignancy with a prevalence of 65,000 patients in North America and an estimated 3000 deaths per year. The addition of the proteasome inhibitor Bortezomib to the treatment protocol in MM has led to a significant improvement in patient survival. However, MM cells eventually acquire resistance to Bortezomib resulting in disease progression and eventually patient death. A small class of genes called microRNA (miRNA), were recently shown to be important in the regulation of cancer cell behaviour. Nearly all transformed cells, including malignant plasma cells, have an altered miRNA expression, although the effect of miRNA on resistance to therapeutics in myeloma is not yet known. Based on our preliminary work, we have postulated that miRNAs are implicated in the acquired drug resistance of MM cells. We have shown that by manipulating miRNA expression in MM cells we are able to increase the cell's sensitivity to Bortezomib. Uncovering the mechanisms of drug resistance will add to our understanding of the biology of this fatal disease and ultimately improve MM patient survival. Upon completion of this project, there will be a greater understanding of the influence of miRNA on the biology of myeloma cells. Subsequently, it may be possible to identify novel therapeutic targets for this incurable disease. The results of this project may have implications to cancer therapy beyond the disease investigated in this project.
Programme
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
257551
Name
Stebner Erin M
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Clinical
Prcname2
Doctoral Research Awards - A
Projecttitle
Influence of microRNA on Resistance to Proteasome Inhibitors in Multiple Myeloma
Programtype2
Studentship Programs
Orgnameinp2
University of Calgary
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Keyworddelim
Cancer Genetics; Fluorescent In Situ Hybridization; Gene Expression Profiling; Hematology; In Vitro Studies; In Vivo Studies; Microarray; Microrna; Multiple Myeloma; Qrt-Pcr
Abstract
Multiple Myeloma (MM), an incurable disease, is the second most common haematological malignancy with a prevalence of 65,000 patients in North America and an estimated 3000 deaths per year. The addition of the proteasome inhibitor Bortezomib to the treatment protocol in MM has led to a significant improvement in patient survival. However, MM cells eventually acquire resistance to Bortezomib resulting in disease progression and eventually patient death. A small class of genes called microRNA (miRNA), were recently shown to be important in the regulation of cancer cell behaviour. Nearly all transformed cells, including malignant plasma cells, have an altered miRNA expression, although the effect of miRNA on resistance to therapeutics in myeloma is not yet known. Based on our preliminary work, we have postulated that miRNAs are implicated in the acquired drug resistance of MM cells. We have shown that by manipulating miRNA expression in MM cells we are able to increase the cell's sensitivity to Bortezomib. Uncovering the mechanisms of drug resistance will add to our understanding of the biology of this fatal disease and ultimately improve MM patient survival. Upon completion of this project, there will be a greater understanding of the influence of miRNA on the biology of myeloma cells. Subsequently, it may be possible to identify novel therapeutic targets for this incurable disease. The results of this project may have implications to cancer therapy beyond the disease investigated in this project.
Competitiondate
201110
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Stebner, Erin M
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~